Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12235412 | 0.88 | GPR119 (0.40) | GPR119CHRM2SCD5JAK1HDAC4 | |
| SCHEMBL15312310 | 0.88 | GPR119 (0.40) | GPR119CHRM2SCD5JAK1HDAC4 | |
| SCHEMBL12235406 | 0.83 | GPR119 (0.45) | GPR119CHRM2SCD5HDAC4HDAC6 | |
| SCHEMBL19262041 | 0.83 | GPR119 (0.45) | GPR119CHRM2SCD5HDAC4HDAC6 | |
| SCHEMBL15312282 | 0.81 | GPR119 (0.39) | GPR119CHRM2SCD5JAK1HDAC4 | |
| SCHEMBL14683713 | 0.78 | JAK1 (0.37) | GPR119SCD5JAK1HDAC4HDAC6 | |
| SCHEMBL15312237 | 0.76 | GPR119 (0.39) | GPR119CHRM2SCD5JAK1HDAC4 | |
| SCHEMBL15144086 | 0.76 | HDAC4 (0.37) | GPR119JAK1HDAC4HDAC6USP30 | |
| SCHEMBL19262068 | 0.76 | GPR119 (0.40) | GPR119CHRM2SCD5JAK1HDAC4 | |
| SCHEMBL14683717 | 0.75 | JAK1 (0.34) | GPR119SCD5JAK1HDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | MITHRIDION, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099956-A1 | Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating | CHRM3, CHRM4, CHRM5 | GPR119 129/4885CHRM2 4/4885SCD5 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.